Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

This is a multicenter, open label, non-inferiority, randomized controlled clinical study. The aim of this study is to evaluate the efficacy and safety of a pegylated liposomal doxorubicin + cyclophosphamide followed by docetaxel plus trastuzumab and pertuzumab (PLD + C + HP followed by THP) regimen compared with a docetaxel + carboplatin plus trastuzumab and pertuzumab (TCbHP) regimen in the neoadjuvant treatment of HER-2-positive breast cancer.

Trial Details

NCT ID
NCT05159193
Phase
PHASE3
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • pegylated liposomal doxorubicin (PLD)
  • cyclophosphamide (C)
  • trastuzumab (H)
  • pertuzumab (P)
  • docetaxel (T)
  • carboplatin (Cb)
Locations (sample)
  • Guandong, Guangdong, China

Key Eligibility Criteria

  • Female patients aged from 18 to 70 years old;
  • Histologically confirmed as invasive breast cancer and without previous treatment.;
  • HER-2 Positive (defined by IHC 3+ or ISH positive);
  • Tumor \> 2cm;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →